Incyte

INCY

Market cap $20.6B

Bill Meury, Incyte president and CEO, joins 'Fast Money' to talk potential M&A, its growth trajectory, its product pipeline, and more.

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Incyte Corporation (INCY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Incyte (INCY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Medicine remains one of the most potentially rewarding of all investment areas. And this biotech stock is flirting with a buy point as analysts see earnings skyrocketing.

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Incyte Corporation remains a Buy, driven by robust Hem/Oncology portfolio growth and key Monjuvi/Minjuvi expansion catalysts. INCY's Hem/Onc portfolio revenues surged 107% YoY in Q3 2025, fueled by Monjuvi/Minjuvi and Niktimvo performance. Positive phase 3 frontMIND data for Monjuvi enables a 1st-line DLBCL sBLA filing in H1 2026, expanding addressable market.

Incyte's phase III study of Monjuvi combo for first-line DLBCL treatment met primary and key secondary goals, paving the way for a 2026 FDA filing.

Incyte Corporation (NASDAQ: INCY) on Monday shared topline results from the pivotal Phase 3 frontMIND trial of tafasitamab (Monjuvi/Minjuvi) combo as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL).

Incyte said on Monday its experimental combo therapy met the main goal in a late-stage trial testing patients with a type of blood cancer.